Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study

Bethea ED, Gaj K, Gustafson JL, et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol. 2019;4:771-780.

Publication Type:

Journal Article

Authors:

Bethea, ED; Gaj, K; Gustafson, JL; et, al

Source:

Lancet Gastroenterol Hepatol, Volume 4, p.771-780 (2019)

Cited On:

Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors

Export Citation:

RIS Format

Top